title: Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation.
abstract: In the Second Annual National Cancer Institute's Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation, the Scientific/Educational Session on the Prevention and Treatment of Relapse after Allogeneic Transplantation highlighted progress in developing new therapeutic approaches since the first relapse workshop. Recent insights that might provide a basis for the development of novel, practical clinical trials were emphasized, including utilization of newer agents, optimization of donor lymphocyte infusion (DLI), and investigation of novel cellular therapies. Dr. de Lima discussed pre-emptive and maintenance strategies to prevent relapse after transplantation, for example, recent promising results suggestive of enhanced graft-versus-tumor activity with hypomethylating agents. Dr. Schmid provided an overview of adjunctive strategies to improve cell therapy for relapse, including cytoreduction before DLI, combination of targeted agents with DLI, and considerations in use of second transplantations. Dr. Porter addressed strategies to enhance T cell function, including ex vivo activated T cells and T cell engineering, and immunomodulatory approaches to enhance T cell function in vivo, including exogenous cytokines and modulation of costimulatory pathways.
authors.affiliation: Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio.
authors.forename: Marcos
authors.initials: M
authors.lastname: de Lima
authors.affiliation: Blood and Marrow Transplantation, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
authors.forename: David L
authors.initials: DL
authors.lastname: Porter
authors.affiliation: Hematology Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland.
authors.forename: Minoo
authors.initials: M
authors.lastname: Battiwalla
authors.affiliation: Section of Hematology/Oncology, University of Chicago Medicine, Chicago, Illinois.
authors.forename: Michael R
authors.initials: MR
authors.lastname: Bishop
authors.affiliation: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.
authors.forename: Sergio A
authors.initials: SA
authors.lastname: Giralt
authors.affiliation: Experimental Transplantation Immunology Branch, National Cancer Institute, Center for Cancer Research, Bethesda, Maryland. Electronic address: hardyn@mail.nih.gov.
authors.forename: Nancy M
authors.initials: NM
authors.lastname: Hardy
authors.affiliation: Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
authors.forename: Nicolaus
authors.initials: N
authors.lastname: Kröger
authors.affiliation: Pediatric Oncology Branch, National Cancer Institute, Center for Cancer Research, Bethesda, Maryland; Current: Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.
authors.forename: Alan S
authors.initials: AS
authors.lastname: Wayne
authors.affiliation: Klinikum Augsburg, University of Munich, Munich, Germany.
authors.forename: Christoph
authors.initials: C
authors.lastname: Schmid
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D064987:Cell- and Tissue-Based Therapy; D006086:Graft vs Host Disease / Q000517:prevention & control; D020350:Graft vs Tumor Effect; D019337:Hematologic Neoplasms / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008212:Lymphocyte Depletion; D019653:Myeloablative Agonists / Q000627:therapeutic use*; D054547:National Cancer Institute (U.S.); D055502:Secondary Prevention; D016019:Survival Analysis; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology / Q000637:transplantation; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D014481:United States
chemical_list: D000970:Antineoplastic Agents; D019653:Myeloablative Agonists
keywords: Allogeneic; Prevention; Relapse; Stem cell transplantation; Treatment
references.citation: Blood. 2000 Oct 15;96(8):2712-6
references.pmid: 11023502
references.citation: Biol Blood Marrow Transplant. 2010 Sep;16(9):1187-211
references.pmid: 20558311
references.citation: Leukemia. 2011 Jan;25(1):181-4
references.pmid: 20944674
references.citation: ScientificWorldJournal. 2011 Feb 03;11:310-9
references.pmid: 21298222
references.citation: Blood. 2012 Feb 9;119(6):1599-606
references.pmid: 22167752
references.citation: Science. 2008 Aug 15;321(5891):974-7
references.pmid: 18703743
references.citation: Biol Blood Marrow Transplant. 2010 Aug;16(8):1037-69
references.pmid: 20580849
references.citation: Bone Marrow Transplant. 1999 Apr;23(8):771-7
references.pmid: 10231138
references.citation: Blood. 2011 Sep 1;118(9):2413-9
references.pmid: 21690556
references.citation: Hematology. 2013 May;18(3):151-7
references.pmid: 23394269
references.citation: Biol Blood Marrow Transplant. 2013 Sep;19(9):1288-300
references.pmid: 23618718
references.citation: N Engl J Med. 2011 Aug 25;365(8):725-33
references.pmid: 21830940
references.citation: Blood. 2011 Nov 17;118(20):5681-8
references.pmid: 21948300
references.citation: Leukemia. 2012 Mar;26(3):381-9
references.pmid: 21886171
references.citation: Biol Blood Marrow Transplant. 2011 Nov;17(11):1679-87
references.pmid: 21664472
references.citation: J Clin Oncol. 1997 Feb;15(2):433-44
references.pmid: 9053463
references.citation: Cancer. 2010 Dec 1;116(23):5420-31
references.pmid: 20672358
references.citation: Nat Rev Clin Oncol. 2012 Oct;9(10):579-90
references.pmid: 22949046
references.citation: Blood. 2010 May 13;115(19):3869-78
references.pmid: 20071660
references.citation: Curr Opin Hematol. 2011 Nov;18(6):388-94
references.pmid: 21897227
references.citation: Blood. 2012 Mar 22;119(12):2956-9
references.pmid: 22289893
references.citation: Curr Opin Hematol. 2002 Nov;9(6):497-502
references.pmid: 12394171
references.citation: Biol Blood Marrow Transplant. 2010 Nov;16(11):1467-503
references.pmid: 20699125
references.citation: Bone Marrow Transplant. 2010 Feb;45(2):349-53
references.pmid: 19584825
references.citation: Blood. 2009 Feb 12;113(7):1581-8
references.pmid: 18974373
references.citation: Clin Trials. 2007;4(2):113-24
references.pmid: 17456511
references.citation: N Engl J Med. 2012 Aug 30;367(9):805-16
references.pmid: 22931314
references.citation: Biol Blood Marrow Transplant. 2010 Oct;16(10):1325-46
references.pmid: 20637879
references.citation: Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S94-100
references.pmid: 21047560
references.citation: Science. 2002 Mar 15;295(5562):2097-100
references.pmid: 11896281
references.citation: Biol Blood Marrow Transplant. 2010 May;16(5):565-86
references.pmid: 20152921
references.citation: J Clin Oncol. 2011 Mar 10;29(8):971-8
references.pmid: 21282545
references.citation: Blood. 2006 Feb 15;107(4):1325-31
references.pmid: 16269610
references.citation: Cancer Treat Rev. 2010 Nov;36(7):528-38
references.pmid: 20381970
references.citation: J Clin Oncol. 2012 Sep 10;30(26):3202-8
references.pmid: 22869883
references.citation: Bone Marrow Transplant. 2008 Dec;42(12):783-9
references.pmid: 18724393
references.citation: Biol Blood Marrow Transplant. 2013 Nov;19(11):1537-45
references.pmid: 24018395
references.citation: Blood. 2011 Sep 22;118(12):3399-409
references.pmid: 21719602
references.citation: J Clin Oncol. 2001 Aug 15;19(16):3675-84
references.pmid: 11504749
references.citation: Blood. 2012 Mar 22;119(12):2709-20
references.pmid: 22160384
references.citation: Br J Haematol. 2012 Feb;156(4):550-2
references.pmid: 21981646
references.citation: J Immunol. 2009 Sep 15;183(6):3598-607
references.pmid: 19710453
references.citation: Blood. 2010 Sep 16;116(11):1908-18
references.pmid: 20530795
references.citation: Clin Cancer Res. 2008 Apr 15;14(8):2484-91
references.pmid: 18413841
references.citation: Blood. 2012 Apr 5;119(14):3361-9
references.pmid: 22234690
references.citation: Biol Blood Marrow Transplant. 2013 Dec;19(12):1661-9
references.pmid: 24018393
references.citation: Biol Blood Marrow Transplant. 2013 Feb;19(2):185-95
references.pmid: 23078782
references.citation: J Clin Oncol. 2002 Jan 15;20(2):405-12
references.pmid: 11786567
references.citation: Blood. 2012 Jun 28;119(26):6379-81
references.pmid: 22611160
references.citation: J Clin Oncol. 2011 Jun 20;29(18):2493-8
references.pmid: 21576633
references.citation: J Clin Invest. 2012 Oct;122(10):3718-30
references.pmid: 22945631
references.citation: Blood. 2010 Jan 7;115(1):107-21
references.pmid: 19887673
references.citation: Bone Marrow Transplant. 2001 Jan;27(1):73-8
references.pmid: 11244440
references.citation: Biol Blood Marrow Transplant. 2013 Jul;19(7):1094-101
references.pmid: 23635453
references.citation: Nat Rev Clin Oncol. 2011 Mar;8(3):151-60
references.pmid: 21364688
references.citation: N Engl J Med. 2013 Apr 18;368(16):1509-1518
references.pmid: 23527958
references.citation: Bone Marrow Transplant. 2012 Aug;47(8):1112-7
references.pmid: 22120986
references.citation: Blood. 2012 Jun 21;119(25):6145-54
references.pmid: 22563089